CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma

Description

The standard treatment for patients with metastatic urothelial cancer is the combination of gemcitabine and cisplatin. Jonathan E. Rosenberg, MD, and colleagues from Memorial Sloan Kettering Cancer Center, New York, evaluated the impact of adding bevacizumab to the combination treatment and determined that it did not improve overall survival. Their results from the phase III CALGB 90601 trial were published in the Journal of Clinical Oncology.